Showing 1711-1720 of 3223 results for "".
- J&J Vision Receives CE Mark Approval for the ELITA Femtosecond Laser Systemhttps://modernod.com/news/jj-vision-receives-ce-mark-approval-for-the-elita-femtosecond-laser-system/2481440/Johnson & Johnson Vision has received CE Mark approval for the ELITA Femtosecond Laser System for laser vision correction. The new laser will allow surgeons to perform refractive correction on patients with myopia, with or without astigmatism, via a new lenticular procedure called t
- Bio-Techne and Narayana Nethralaya Collaborate On the Use of Ella for Ophthalmic Disorder Diagnostic Applicationshttps://modernod.com/news/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications/2479224/Bio-Techne announced a collaboration with Narayana Nethralaya to develop a diagnostic solution for ophthalmology disorders on its ProteinSimple branded, multiplexing immunoassay instrument, Ella. The Ella platform, which is currently sold for research use only, allows users to perform high-qualit
- Ocumension Therapeutics Licenses Alimera’s Fluocinolone Acetonide Intravitreal Implant in Chinahttps://modernod.com/news/ocumension-therapeutics-licenses-alimeras-fluocinolone-acetonide-intravitreal-implant-in-china/2479075/Alimera Sciences announced that Ocumension Therapeutics has acquired an exclusive license agreement for Alimera’s 0.19mg fluocinolone acetonide intravitreal implant, which Alimera markets elsewhere under the trademark Iluvien. The license grants Ocumension the rights to develop and commercialize
- Allscripts, Microsoft Strike 5-Year Cloud Partnership to Enhance EHR Softwarehttps://modernod.com/news/allscripts-microsoft-strike-5-year-cloud-partnership-to-enhance-ehr-software/2478012/Allscripts is extending its partnership with Microsoft to use the tech giant’s cloud technology to enhance its electronic health record (EHR) software, according to a FierceHealthcare
- NIAID Launches ACTT 2 Trial Testing Gilead’s Remdesivir Plus Eli Lilly, Incyte’s JAK Inhibitor Olumiant in COVID-19https://modernod.com/news/niaid-launches-actt-2-trial-testing-gileads-remdesivir-plus-eli-lilly-incytes-jak-inhibitor-olumiant-in-covid-19/2477741/The US National Institute of Allergy and Infectious Diseases (NIAID) said Friday that it is enrolling hospitalized adults with COVID-19 in the US to take part in a study evaluating the combination of Gilead Sciences’ remdesivir with Eli Lilly and Incyte’s JAK inhibitor Olumiant as a p
- Altered Visual Processing a Nonverbal Marker of Autism?https://modernod.com/news/altered-visual-processing-a-nonverbal-marker-of-autism/2476838/Patients with autism may have altered visual processing, which could serve as an objective, nonverbal neural marker of the disorder, new research suggests, according to a Medscape report. Using electroencephalography (EEG), investi
- Bausch + Lomb Introduces 23-Gauge Bi-Blade Dual Port Vitrectomy Cutter for the Stellaris Elite Vision Enhancement Systemhttps://modernod.com/news/bausch-lomb-introduces-23-gauge-bi-blade-dual-port-vitrectomy-cutter-for-the-stellaris-elite-vision-enhancement-system/2476752/Bausch + Lomb announced the introduction of the 23-gauge Bi-Blade dual port vitrectomy cutter for the Stellaris Elite vision enhancement system. The new probe joins the available 25- and 27-gauge Bi-Blade cutters as options in the Bi-Blade portfolio. All Bi-Blade cutters double effective cut rate
- More Elderly Americans Dying From Fallshttps://modernod.com/news/more-elderly-americans-dying-from-falls/2476634/Death rates from falls are rising among elderly Americans and climbing fastest among seniors in their 90s, a US study suggests. Among all adults 75 and older, mortality from falls climbed 5.1% from 2000 to 2016, researchers report in JAMA. Death rates from falls rose the most—6.4%—among
- Aldeyra Therapeutics Provides Update on Ophthalmic Programshttps://modernod.com/news/aldeyra-therapeutics-provides-update-on-ophthalmic-programs/2476256/Aldeyra Therapeutics updated progress on ophthalmic programs at a 2019 Research & Development Day in New York City. Presentations were given by members of the Aldeyra executive team along with Dean Eliott, MD, the Stelios Evangel
- BlephEx Names Fred Ellis CEOhttps://modernod.com/news/blephex-names-fred-ellis-ceo/2480014/BlephEx has announced that Fred Ellis is the company’s new CEO. Mr. Ellis comes to BlephEx with 29+ years of experience with Alcon-Novartis. While there, he held numerous positions of increased responsibility overseeing a wide range of commercial assignments. He is recognized for having exception